Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 21 June 2027 to 25 June 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 21 June 2027 to 25 June 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 24 May 2027 to 28 May 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 24 May 2027 to 28 May 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 12 April 2027 to 16 April 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 12 April 2027 to 16 April 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 8 March 2027 to 12 March 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 8 March 2027 to 12 March 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 1 February 2027 to 5 February 2027

Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance system, Online, from 1 February 2027 to 5 February 2027

Human medicines European public assessment report (EPAR): Jascayd, nerandomilast, Date of authorisation: 15/07/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Jascayd, nerandomilast, Date of authorisation: 15/07/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Herceptin, trastuzumab, Date of authorisation: 28/08/2000, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Herceptin, trastuzumab, Date of authorisation: 28/08/2000, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Date of authorisation: 09/12/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Date of authorisation: 09/12/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 7, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.